



Liste modèle des médicaments essentiels



Amikacin [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)

Indications

Premier choix

[Neutropenia \(high-risk\)](#) co-prescrire avec [cefotaxime Inflammatory and other diseases of prostate \(severe\)](#) co-prescrire avec [cefotaxime Acute pyelonephritis \(severe\)](#) co-prescrire avec [ceftriaxone Inflammatory and other diseases of prostate \(severe\)](#) co-prescrire avec [ceftriaxone Acute pyelonephritis \(severe\)](#)

Second choix

co-prescrire avec [cloxacillin Sepsis without septic shock](#)

Section

Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Amoxicillin [Informations générales](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

Premier choix

[Acute pharyngitis](#) [Periapical abscess without sinus](#) [Acute sinusitis](#) [Acute otitis media](#) [Chronic obstructive](#)

[pulmonary disease with acute exacerbation](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(uncomplicated\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescrire avec [gentamicin](#) [Sepsis without septic shock](#)

Second choix

[Bacterial meningitis](#)

Autres indications

[Bacterial infection of unspecified site](#) [Infectious cystitis](#)



Amoxicillin + clavulanic acid [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

Premier choix

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Infectious cystitis](#) [Neutropenia \(low-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Peritonitis \(mild-moderate\)](#) [Acute sinusitis](#) [Peritoneal abscess \(mild-moderate\)](#) [Chronic obstructive pulmonary disease with acute exacerbation](#)

Second choix

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Bacterial infection of joint](#) [Other specified prophylactic measures](#) [Osteomyelitis or osteitis](#) [Acute otitis media](#)

Autres indications

[Bacterial infection of unspecified site](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Ampicillin [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

Premier choix

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) co-prescrire avec [gentamicin](#) [Sepsis without septic shock](#)

Second choix

[Bacterial meningitis](#)

Autres indications

[Bacterial infection of unspecified site](#)



Azithromycin [Informations générales](#)

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

Premier choix

[Trachoma Cholera Cholera \[children\] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws](#) co-prescrire avec [ceftriaxone Gonococcal infection](#)

Second choix

[Infectious gastroenteritis or colitis without specification of infectious agent](#) co-prescrire avec [cefixime Gonococcal infection](#)

Aztreonam [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Bedaquiline [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Benzathine benzylpenicillin [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection

Indications

Premier choix

[Congenital syphilis \[children\] Syphilis](#)

Autres indications

[Bacterial infection of unspecified site](#)

Benzylpenicillin [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

Premier choix

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\] Congenital syphilis \[children\] Syphilis Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescrire avec [gentamicin Sepsis without septic shock](#)

Second choix

[Bacterial meningitis](#)

Autres indications

[Bacterial infection of unspecified site](#)

Capreomycin [Informations générales](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Cefalexin [Informations générales](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

Premier choix

[Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choix

[Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis](#)

Autres indications

[Bacterial infection of unspecified site](#)

Cefazolin [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

Premier choix

[Other specified prophylactic measures Other specified prophylactic measures](#)

Second choix

[Bacterial infection of joint Osteomyelitis or osteitis](#)

Autres indications

[Surgical site infection](#)

Cefepime [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

[Other specified bacterial diseases](#)

Cefiderocol [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

Cefixime [Informations générales](#)

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choix

[Infectious gastroenteritis or colitis without specification of infectious agent](#) [Gonococcal infection](#)

Cefotaxime [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

Premier choix

[Bacterial meningitis](#) [Inflammatory and other diseases of prostate \(severe\)](#) [Acute pyelonephritis \(severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#)

Second choix

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Sepsis without septic shock](#) [Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

Autres indications

[Bacterial infection of unspecified site](#)

Ceftaroline [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

[Other specified bacterial diseases](#)

Ceftazidime [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

Premier choix

[Endophthalmitis](#)

Autres indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

Ceftazidime + avibactam [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Ceftolozane + tazobactam [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)



Ceftriaxone [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

Premier choix

[Inflammatory and other diseases of prostate \(severe\)](#) [Bacterial meningitis](#) [Acute pyelonephritis \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Paratyphoid fever](#) [Typhoid fever](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Gonococcal infection](#) [Endophthalmitis](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [children] co-prescrire avec [metronidazole](#) [Necrotising fasciitis](#)

Second choix

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Bacterial infection of joint](#) [Sepsis without septic shock](#) [Osteomyelitis or osteitis](#)

Autres indications

[Bacterial infection of unspecified site](#)



Cefuroxime [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choix

[Other specified prophylactic measures](#)



Chloramphenicol [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

Indications

Second choix

[Bacterial meningitis](#)

Autres indications

[Bacterial infection of unspecified site](#)



Ciprofloxacin [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

Premier choix

[Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Paratyphoid fever](#) [Typhoid fever](#) [Neutropenia \(low-risk\)](#) [Inflammatory and other diseases of prostate \(mild to moderate\)](#)

Second choix

[Cholera](#) [Cholera \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

Autres indications

[Bacterial infection of unspecified site](#)

Clarithromycin [Informations générales](#)

Section

Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

Indications

Premier choix

co-prescrire avec [cefotaxime](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) co-prescrire avec [ceftriaxone](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Second choix

[Acute pharyngitis](#) co-prescrire avec [amoxicillin + clavulanic acid](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Autres indications

[Helicobacter pylori associated gastric ulcer](#)

Clindamycin [Informations générales](#)

Section

Access group antibiotics

- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)

Indications

Premier choix

[Necrotising fasciitis](#)

Second choix

[Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

Autres indications

[Bacterial infection of unspecified site](#)

Clofazimine [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Section

Antileprosy medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Leprosy](#)



Cloxacillin [Informations générales](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

Premier choix

[Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choix

[Sepsis without septic shock](#)

Autres indications

[Bacterial infection of unspecified site](#)



Colistin (injection) [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

[Other specified bacterial diseases](#) [Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)



Cycloserine [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 250 mg; 125 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Dapsone [Informations générales](#)

Section

Antileprosy medicines

- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

[Leprosy](#)



Daptomycin [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Delafloxacin [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

Delamanid [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Dicloxacillin [Informations générales](#)

Section

Access group antibiotics

Indications

Premier choix

Therapeutic equivalent to [cloxacillin](#) pour [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choix

Therapeutic equivalent to [cloxacillin](#) pour [Sepsis without septic shock](#)

Doxycycline [Informations générales](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

Premier choix

[Cholera Chlamydia trachomatis](#)

Second choix

[Cholera \[children\]](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#)

Autres indications

[Bacterial infection of unspecified site](#)

Eravacycline [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

[Carbapenem resistant Enterobacterales](#)

Erythromycin [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choix

Therapeutic equivalent to [clarithromycin](#) pour [Acute pharyngitis](#)

Autres indications

[Bacterial infection of unspecified site](#)

Ethambutol [Informations générales](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

[Other specified tuberculosis Tuberculosis](#)

Ethambutol + isoniazid [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid: 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)

Ethambutol + isoniazid + pyrazinamide + rifampicin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)

Ethambutol + isoniazid + rifampicin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

[Tuberculosis](#)

Ethionamide [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg

Indications

[Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis](#)

Fifth generation cephalosporins [Informations générales](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Flomoxef [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)

Flucloxacillin [Informations générales](#)

Section

Access group antibiotics

Indications

Premier choix

Therapeutic equivalent to [cloxacillin](#) pour [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choix

Therapeutic equivalent to [cloxacillin](#) pour [Sepsis without septic shock](#)

Fosfomycin (injection) [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

[Other specified bacterial diseases](#) [Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Fourth generation cephalosporins [Informations générales](#)

Section

Watch group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Gatifloxacin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Gentamicin [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

Premier choix

[Neonatal meningitis](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) co-prescribe avec [amoxicillin](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribe avec [ampicillin](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribe avec [ampicillin](#) [Peritonitis \(mild-moderate\)](#) co-prescribe avec [ampicillin](#) [Peritonitis \(severe\)](#) co-prescribe avec [ampicillin](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribe avec [ampicillin](#) [Peritoneal abscess \(severe\)](#) co-prescribe avec

[ampicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescrire avec [benzylpenicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescrire avec [benzylpenicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

Second choix

[Gonococcal infection Other specified prophylactic measures](#)

Autres indications

[Bacterial infection of unspecified site](#)

Imipenem + cilastatin [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

Second choix

Therapeutic equivalent to [meropenem](#) pour [Peritonitis \(severe\)](#) Therapeutic equivalent to [meropenem](#) pour [Peritoneal abscess \(severe\)](#) Therapeutic equivalent to [meropenem](#) pour [Neutropenia \(high-risk\)](#)

Autres indications

[Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [meropenem](#) pour [Multi-drug resistant Mycobacterium tuberculosis](#)

Imipenem + cilastatin + relebactam [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

[Carbapenem resistant Enterobacterales Other specified other antibiotic resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa](#)

Isoniazid [Informations générales](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 100 mg per mL
- Oral > Solid > dispersible tablet: 100 mg (scored)
- Oral > Solid > tablet: 100 mg; 300 mg

Indications

[Other specified tuberculosis Tuberculosis](#)

Isoniazid + pyrazinamide + rifampicin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

[Tuberculosis](#)

Isoniazid + rifampicin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

[Tuberculosis](#)

Isoniazid + rifapentine [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

[Latent tuberculosis](#)

Kanamycin (injection) [Informations générales](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Levofloxacin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Linezolid [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Indications

[Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg (scored)
- Oral > Solid > tablet: 600 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Meropenem [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choix

[Neonatal meningitis Peritonitis \(severe\) Peritoneal abscess \(severe\) Neutropenia \(high-risk\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Meropenem + vaborbactam [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#) [Carbapenem resistant Acinetobacter baumannii](#)



Meticillin [Informations générales](#)

Section
Access group antibiotics
Indications

Premier choix

Therapeutic equivalent to [cloxacillin](#) pour [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choix

Therapeutic equivalent to [cloxacillin](#) pour [Sepsis without septic shock](#)



Metronidazole [Informations générales](#)

Section
Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg

Indications

Premier choix

[Intestinal infections due to Clostridioides difficile](#) [Trichomoniasis](#) [Necrotising fasciitis](#) co-prescrire avec [cefazolin](#) [Other specified prophylactic measures](#) co-prescrire avec [cefotaxime Peritoneal abscess \(mild-moderate\)](#) co-prescrire avec [cefotaxime Peritoneal abscess \(severe\)](#) co-prescrire avec [cefotaxime Peritonitis \(mild-moderate\)](#) co-prescrire avec [cefotaxime Peritonitis \(severe\)](#) co-prescrire avec [ceftriaxone Peritoneal abscess \(mild-moderate\)](#) co-prescrire avec [ceftriaxone Peritoneal abscess \(severe\)](#) co-prescrire avec [ceftriaxone Peritonitis \(mild-moderate\)](#) co-prescrire avec [ceftriaxone Peritonitis \(severe\)](#)

Second choix

co-prescrire avec [ciprofloxacin Peritoneal abscess \(mild-moderate\)](#) co-prescrire avec [ciprofloxacin Peritonitis \(mild-moderate\)](#)

Autres indications

[Bacterial infection of unspecified site](#)



Moxifloxacin [Informations générales](#)

Section
Antituberculosis medicines

- Oral > Solid > tablet: 400 mg
- Oral > Solid > dispersible tablet: 100 mg

Indications

[Tuberculosis Multi-drug resistant Mycobacterium tuberculosis](#)



Nafcillin [Informations générales](#)

Section
Access group antibiotics
Indications

Premier choix

Therapeutic equivalent to [cloxacillin](#) pour [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choix

Therapeutic equivalent to [cloxacillin](#) pour [Sepsis without septic shock](#)

Nitrofurantoin [Informations générales](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

Premier choix

[Infectious cystitis](#)

Ofloxacin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Omadacycline [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

Oxacillin [Informations générales](#)

Section

Access group antibiotics

Indications

Premier choix

Therapeutic equivalent to [cloxacillin](#) pour [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) pour [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choix

Therapeutic equivalent to [cloxacillin](#) pour [Sepsis without septic shock](#)

Oxazolindinones [Informations générales](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

P-aminosalicylate sodium [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

P-aminosalicylic acid [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid: 4 g granules in sachet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Phenoxyethylpenicillin [Informations générales](#)

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

Premier choix

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\) Periapical abscess without sinus Acute pharyngitis](#)

Autres indications

[Bacterial infection of unspecified site](#)



Piperacillin + tazobactam [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

Premier choix

[Neutropenia \(high-risk\) Other specified pneumonia \(Hospital-acquired pneumonia\) Peritonitis \(severe\) Peritoneal abscess \(severe\)](#) co-prescrire avec [clindamycin](#) [Necrotising fasciitis](#)



Plazomicin [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

[Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)



Polymyxin B (injection) [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

[Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)



Polymyxins [Informations générales](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)



Pretomanid [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 200 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Procaine benzylpenicillin [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

Premier choix

[Congenital syphilis \[children\]](#)

Second choix

[Syphilis](#)

Protionamide [Informations générales](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [ethionamide](#) pour [Multi-drug resistant Mycobacterium tuberculosis](#)

Pyrazinamide [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg

Indications

[Tuberculosis](#)

Rifabutin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid: 150 mg

Indications

[Tuberculosis](#)

Rifampicin [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
- Parenteral > General injections > IV: 600 mg in vial powder for injection

Indications

[Tuberculosis Other specified tuberculosis](#)

Section

Antileprosy medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg

Indications

[Leprosy](#)

Rifapentine [Informations générales](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 150 mg

Indications

[Tuberculosis Latent tuberculosis](#)

Spectinomycin [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choix

[Gonococcal infection](#)

Autres indications

[Bacterial infection of unspecified site](#)

Streptomycin (injection) [Informations générales](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Sulfamethoxazole + trimethoprim [Informations générales](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

Premier choix

[Infectious cystitis](#)

Second choix

[Infectious gastroenteritis or colitis without specification of infectious agent](#)

Autres indications

[Bacterial infection of unspecified site](#)

Tedizolid [Informations générales](#)

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) pour [Methicillin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) pour [Vancomycin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) pour [Vancomycin resistant Enterococcus](#)

Terizidone [Informations générales](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [cycloserine](#) pour [Multi-drug resistant Mycobacterium tuberculosis](#)

Tetracycline [Informations générales](#)

Section

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Indications

[Bacterial infection of unspecified site](#)

Tigecycline [Informations générales](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Trimethoprim [Informations générales](#)

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

Premier choix

[Infectious cystitis](#)

Vancomycin [Informations générales](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

Premier choix

[Necrotising fasciitis](#) co-prescrire avec [ceftazidime Endophthalmitis](#) co-prescrire avec [ceftriaxone Endophthalmitis](#)

Second choix

[Intestinal infections due to Clostridioides difficile Neutropenia \(high-risk\)](#)

Autres indications

[Methicillin resistant Staphylococcus aureus](#)